Loading basket contents...
HIV Drug Resistance EQA/PT Scheme
To assess the performance of laboratories in the detection of drug resistance mutations in the HIV-1 protease, reverse transcriptase, and integrase genes.
Total Number of Challenges: 1
Number of Panel Members: 4
Distribution / Testing Period: Q4
| Sample NA Target Source | Cultured and/or Clinical material |
| Matrix Panel Format | Plasma |
| Panel Member Target Range | Various mutations – protease (PR), reverse transcriptase (RT) and integrase (INT) genes |
| Panel Member Sample Volume | 1.0 ml |
| Panel Sample Pre-treatment Requirement | Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Analysis Type | Sequence Analysis |
| Panel Testing | Evaluated by various molecular methodologies |
| Storage / Shipment Conditions | <-20°C / Frozen on Dry-ice |
| Accreditation / Regulatory Status | Accredited to ISO 17043 |
$1,426.53
You may also like…
-
SKU: HIVMQC
-
SKU: HIVRNAEP
